1. Home
  2. ESEA vs NKTX Comparison

ESEA vs NKTX Comparison

Compare ESEA & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Euroseas Ltd. (Marshall Islands)

ESEA

Euroseas Ltd. (Marshall Islands)

HOLD

Current Price

$55.90

Market Cap

432.9M

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$1.85

Market Cap

129.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESEA
NKTX
Founded
2005
2015
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
432.9M
129.3M
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
ESEA
NKTX
Price
$55.90
$1.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$62.00
$13.25
AVG Volume (30 Days)
36.5K
665.2K
Earning Date
11-18-2025
11-10-2025
Dividend Yield
4.96%
N/A
EPS Growth
6.77
N/A
EPS
17.38
N/A
Revenue
$223,794,428.00
N/A
Revenue This Year
$10.05
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.25
N/A
Revenue Growth
7.26
N/A
52 Week Low
$26.30
$1.31
52 Week High
$66.00
$2.74

Technical Indicators

Market Signals
Indicator
ESEA
NKTX
Relative Strength Index (RSI) 48.74 48.88
Support Level $51.00 $1.79
Resistance Level $57.10 $1.90
Average True Range (ATR) 2.47 0.06
MACD -0.03 0.01
Stochastic Oscillator 61.52 70.00

Price Performance

Historical Comparison
ESEA
NKTX

About ESEA Euroseas Ltd. (Marshall Islands)

Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: